Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-12-12
1996-08-13
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514561, 514564, 514930, A61K 3170, A61K 31195
Patent
active
055456251
ABSTRACT:
Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of .alpha..sub.1 -adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate synthetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine induced hypotension.
REFERENCES:
patent: 4775623 (1988-10-01), Katsumata et al.
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5059712 (1991-10-01), Griffith
patent: 5196195 (1993-03-01), Griffith et al.
patent: 5216025 (1993-06-01), Gross et al.
patent: 5364881 (1994-11-01), Griffith et al.
patent: 5424447 (1995-06-01), Griffith et al.
patent: 5464858 (1995-11-01), Griffith et al.
Carignan, J. A., et al, Hosp. Formul. 21, 1025-1030 and 1033 (1986).
Corbett, J. A., et al, J. Clin. Invest. 90, 2384-2391 (1992).
Jinno, Y., et al, EMBL Database, Sequence from J. Biochem. 98, 1395-1403 (1985).
Kleeman, R., et al, FEBS, 328, 9-12 (Aug. 1993).
Nussler, A. K. et al, J. Biol. Chem., 269, 1257-1261 (1994).
Schmidt, H. H. H. W., et al, Eur. J. Pharmacol., 148, 293-295 (1988).
Corbett, J. A., et al, Proc. Natl. Acad. Sci. USA, 90, 1731-1735 (Mar. 1993).
Corbett, J. A., et al, Proc. Natl. Acad. Sci. USA, 90, 8992-8995 (Oct. 1993).
Kroncke, K-D, et al, Biochem. Biophys. Res. Commun. 175, 752-758 (1991).
Lukic, M. L., et al, Biochem. Biophys. Res. Commun. 178, 913-920 (1991).
Schmidt, H. H. H. W., et al, Eur. J. Pharmacol,. 154, 213-216 (1988).
Sessa, W. C., et al, Proc. Natl. Acad. Sci. USA, 87,8607-8611 (Nov. 1990).
Corbett, J. A., et al, Biochemistry 32, 13767-13770 (1993).
Cross, A. H., et al, J. Clin. Invest. 93, 2684-2690 (1994).
McCartney-Francis, N., et al, J. Exp. Med. 178, 749-754 (1993).
Misko, T. P., et al, Eur. J. Pharmacol. 233, 119-125 (1993).
Suarez-Pinzon, W. L., et al, Endocrinology, 134, 1006-1010 (1994).
Takada, S., et al, J. Biochem. 85, 1309-1314 (1979).
Freytag, S. O., Medline Abstract of J. Biol. Chem., 259, 3160-6 (1984).
Grisolia, S., et al, The Urea Cycle, John Wiley & Sons, p. 191 (1976).
Mitchell, J. A., et al, Eur. J. Pharmacol., 182, 573-576 (1990).
Mulligan, M. S., et al, Proc. Natl. Acad. Sci. USA, 88, 6338-6342 (Jul. 1991).
Weinberg, J. B., et al, J. Exp. Med. 148, 651-660 (Feb. 1994).
Wu, G., et al, Biochem. J., 281, 45-48 (1992).
Hattori, Y., et al, J. Biol. Chem. 269, 9405-9408 (1994).
Ialenti, A., et al, Eur. J. Pharmacol. 211, 177-182 (1992).
Mulligan, M. S., et al, Br. J. Pharmacol., 107, 1159-1162 (1992).
Nathan, C. F., et al, Current Opinion in Immunology, 3, 65-70 (1991).
Yang, X., et al, J. Clin. Invest., 94, 714-721 (1994).
Griffith Owen W.
Gross Steven S.
Jordan Kimberly
The Medical College of Wisconsin Research Foundation Inc.
LandOfFree
Preventing conversion of citrulline to argininosuccinate to limi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing conversion of citrulline to argininosuccinate to limi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing conversion of citrulline to argininosuccinate to limi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1047981